Long‐acting insulin analogues and the risk of diabetic nephropathy among patients with type 2 diabetes: A population‐based cohort study
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70397 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Julia Brillinger und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetic Nephropathies, Insulin, Long-Acting, Hypoglycemic Agents. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
The risk of diabetic nephropathy among patients with type 2 diabetes (T2D) can be reduced through optimal glycaemic control. It is not known if the pharmacological properties of long‐acting insulin analogues may reduce the risk of diabetic complications compared with neutral protamine Hagedorn (NPH) insulin. We compared the risk of diabetic nephropathy associated with the use of long‐acting insulin analogues with the use of intermediate‐acting NPH insulin among patients with T2D. Materials and Methods We conducted a retrospective cohort study using an active‐comparator, new user design and the United Kingdom's Clinical Practice Research Datalink AURUM. Our primary outcome was incident diabetic nephropathy, and our secondary outcomes were chronic kidney disease (CKD) and end‐stage renal disease (ESRD). We used Cox proportional hazards models with inverse probability of treatment weighting to estimate hazard ratios (HR) and 95% confidence intervals (CI) for each outcome associated with long‐acting insulin analogues versus NPH insulin.
Results
The incidence rate (per 1000 person‐years) of diabetic nephropathy was 16.3 (95% CI: 15.3–17.4) among initiators of long‐acting insulin analogues and 17.5 (95% CI: 16.3–18.8) among initiators of NPH insulin. Compared with NPH insulin, long‐acting insulin analogues were not associated with the risk of diabetic nephropathy (adjusted HR: 0.94, 95% CI: 0.85–1.04). The adjusted HR was 0.91 (95% CI: 0.88–0.94) for CKD and 0.78 (95% CI: 0.46–1.32) for ESRD.
Conclusions
We did not find an association between use of a long‐acting insulin analogue, compared with use of NPH insulin, and the risk of diabetic nephropathy among patients with T2D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.
- Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada.
- Department of Pediatrics, McGill University, Montreal, Quebec, Canada.
- Department of Medicine, McGill University, Montreal, Quebec, Canada.
ORCID-Profile: Kristian B Filion
Zitieren
APA
Brillinger, J., Filliter, C., Salmasi, S., Zapata-Bravo, E., Platt, R. W., Yu, O. H. Y., & Filion, K. B. (2026). Long‐acting insulin analogues and the risk of diabetic nephropathy among patients with type 2 diabetes: A population‐based cohort study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70397
Vancouver
Brillinger J, Filliter C, Salmasi S, Zapata-Bravo E, Platt RW, Yu OHY, et al. Long‐acting insulin analogues and the risk of diabetic nephropathy among patients with type 2 diabetes: A population‐based cohort study. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70397
BibTeX
@article{Brillinger2026,
author = {Brillinger, Julia and Filliter, Christopher and Salmasi, Shahrzad and Zapata-Bravo, Estefania and Platt, Robert W and Yu, Oriana H Y and Filion, Kristian B},
title = {Long‐acting insulin analogues and the risk of diabetic nephropathy among patients with type 2 diabetes: A population‐based cohort study},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70397}
}
EUVIMED